Randomized Open Label Trial of Vigil in Combination with Irinotecan and Temozolomide as a Second Line Regimena for Ewing Sarcoma (CL-PTL-130)
Randomized Open Label Trial of Vigil in Combination with Irinotecan and Temozolomide as a Second Line Regimena for Ewing Sarcoma (CL-PTL-130)
Trial Category:
Sarcoma
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
Vigil=Bi-SHRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
